Cresco Labs Statistics
Total Valuation
Cresco Labs has a market cap or net worth of 340.58 million. The enterprise value is 736.51 million.
Market Cap | 340.58M |
Enterprise Value | 736.51M |
Important Dates
The last earnings date was Wednesday, August 6, 2025.
Earnings Date | Aug 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 338.76M |
Shares Outstanding | n/a |
Shares Change (YoY) | +2.67% |
Shares Change (QoQ) | +1.16% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 332.94M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 0.50 |
PB Ratio | 0.94 |
P/TBV Ratio | n/a |
P/FCF Ratio | 3.79 |
P/OCF Ratio | 2.88 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.33, with an EV/FCF ratio of 8.19.
EV / Earnings | -16.12 |
EV / Sales | 1.10 |
EV / EBITDA | 4.33 |
EV / EBIT | 8.34 |
EV / FCF | 8.19 |
Financial Position
The company has a current ratio of 3.10, with a Debt / Equity ratio of 1.75.
Current Ratio | 3.10 |
Quick Ratio | 1.84 |
Debt / Equity | 1.75 |
Debt / EBITDA | 3.66 |
Debt / FCF | 7.02 |
Interest Coverage | 1.51 |
Financial Efficiency
Return on equity (ROE) is -9.89% and return on invested capital (ROIC) is 5.46%.
Return on Equity (ROE) | -9.89% |
Return on Assets (ROA) | 4.13% |
Return on Invested Capital (ROIC) | 5.46% |
Return on Capital Employed (ROCE) | 7.17% |
Revenue Per Employee | 233,568 |
Profits Per Employee | -15,751 |
Employee Count | 2,900 |
Asset Turnover | 0.50 |
Inventory Turnover | 3.75 |
Taxes
In the past 12 months, Cresco Labs has paid 52.58 million in taxes.
Income Tax | 52.58M |
Effective Tax Rate | 324.55% |
Stock Price Statistics
The stock price has decreased by -47.00% in the last 52 weeks. The beta is 1.40, so Cresco Labs's price volatility has been higher than the market average.
Beta (5Y) | 1.40 |
52-Week Price Change | -47.00% |
50-Day Moving Average | 0.63 |
200-Day Moving Average | 0.83 |
Relative Strength Index (RSI) | 70.25 |
Average Volume (20 Days) | 1,585,768 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cresco Labs had revenue of 677.35 million and -45.68 million in losses. Loss per share was -0.13.
Revenue | 677.35M |
Gross Profit | 331.63M |
Operating Income | 89.40M |
Pretax Income | 16.20M |
Net Income | -45.68M |
EBITDA | 143.34M |
EBIT | 89.40M |
Loss Per Share | -0.13 |
Balance Sheet
The company has 146.61 million in cash and 630.91 million in debt, giving a net cash position of -484.30 million.
Cash & Cash Equivalents | 146.61M |
Total Debt | 630.91M |
Net Cash | -484.30M |
Net Cash Per Share | n/a |
Equity (Book Value) | 360.91M |
Book Value Per Share | 1.25 |
Working Capital | 213.28M |
Cash Flow
In the last 12 months, operating cash flow was 118.14 million and capital expenditures -28.22 million, giving a free cash flow of 89.93 million.
Operating Cash Flow | 118.14M |
Capital Expenditures | -28.22M |
Free Cash Flow | 89.93M |
FCF Per Share | n/a |
Margins
Gross margin is 48.96%, with operating and profit margins of 13.20% and -6.74%.
Gross Margin | 48.96% |
Operating Margin | 13.20% |
Pretax Margin | 2.39% |
Profit Margin | -6.74% |
EBITDA Margin | 21.16% |
EBIT Margin | 13.20% |
FCF Margin | 13.28% |
Dividends & Yields
Cresco Labs does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -2.67% |
Shareholder Yield | n/a |
Earnings Yield | -13.41% |
FCF Yield | 26.40% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Cresco Labs has an Altman Z-Score of -0.3 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.3 |
Piotroski F-Score | 5 |